Medical Device

Via InvestorWireIBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell's latest podcast features Hector Bremner, CEO of Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) , a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward.

Throughout the interview, Bremner discussed Avricore's business model and the company's continuing efforts to lead the charge and improve early detection and screening practices throughout the health care industry.

"We're a company focused on diagnostics. We place a system within the pharmacy where a blood test or a molecular test can be done. A simple sample is collected, and the whole test takes about 15 minutes," Bremner said. "Our technology is a cloud-based solution that networks these high-quality analyzers from companies like Abbott and is able to then create a testing network in the pharmacy… The patient gets to keep their information, of course… but really, the objective here is to create a global network of pharmacies reporting back real-time information on patient data that can be used for study and research purposes, which is a very, very high demand out there in the sector."

"My background, funnily enough, was not in health care nor public companies. I was actually in government," he continued. "Leading into Avricore Health, what got me excited was that we have a disease care system in [Canada], and I've always really believed that we need a true health care system that values early detection and screening if we really want to make sure that we're not only saving lives but saving health care dollars in the future. We're really passionate about leading this charge… We've got a company that is in great shape and fully funded. We're growing, and we've got a lot of blue sky ahead of us."

Bremner then discussed some of the recent milestones for Avricore Health.

"One milestone that I'm really proud of is that by the late summer/early fall of 2020, we had begun discussions with Abbott Diagnostics . Ultimately, we concluded multiple distribution agreements with them, which was pretty groundbreaking in the sense that they do not do distribution agreements for their technology with third-party technology companies like us," he noted. "Normally, to distribute Abbott technologies at this level, you have to be a fairly large distributor of health care technologies to begin with. We were extremely fortunate to pioneer this agreement and really break ground to see what was possible as a value-added reseller to bring our technology in combination with theirs. This has really been a jump-off point for us; it's really accelerated our growth."

Join IBN's Stuart Smith and Hector Bremner, CEO of Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) , to learn more about the company's recent agreement with Shoppers Drug Mart and its goals for the balance of 2021 and beyond.

To hear the episode and subscribe to future podcasts, visit https://podcast.bell2bell.com .

The latest installment of The Bell2Bell Podcast continues to reinforce IBN's commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series . For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies .

To learn more about IBN's achievements and milestones via a visual timeline, visit https://IBN.fm/TimeLine .

About Avricore Health Inc.

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through flagship offering HealthTab™ (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies. For more information, visit the company's website at www.AvricoreHealth.com .

About IBN

IBN (InvestorBrandNetwork) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire ("NNW") and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information, please visit https://www.InvestorBrandNetwork.com .

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

avricore

Avricore Health


Keep reading...Show less

Medtronic executives to speak at the Evercore ISI 5th annual HealthCONx conference

- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the Evercore ISI 5 th annual HealthCONx conference on Tuesday, November 29 2022.

Geoff Martha , Medtronic chairman and chief executive officer, and Karen Parkhill , executive vice president & chief financial officer, will answer questions on the company beginning at 5:10 p.m. EST ( 4:10 p.m. CST ).

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
2 Biggest Medical Device ETFs in 2022

2 Biggest Medical Device ETFs in 2022

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less

Medtronic reports second quarter fiscal 2023 financial results

Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.S. Core Spine, and International Diabetes

Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2023, which ended October 28, 2022 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Present at Evercore ISI HealthCONx Conference

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 10:30 a.m. (EST).

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology

  • The Consumer Technology Association (CTA) awards Abbott multiple CES 2023 Innovation Awards for industry-leading health technologies
  • Abbott's Aveir™ single-chamber (VR) leadless pacemaker, Proclaim™ Plus SCS system, Alinity ® m Monkeypox PCR test honored
  • Other recent Abbott innovation honors include Abbott's FreeStyle Libre ® technology named the best medical technology in the last 50 years by the Galien Foundation

- Abbott (NYSE: ABT) has been recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide. The CTA is the organization behind the Consumer Electronics Show (CES), the most influential technology event in the world.

Ahead of the CES 2023 event, three of Abbott's industry-leading tech advancements won CES 2023 Innovation Awards , all within the Digital Health award category:

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") announced today that on November 14, 2022 it priced an offering of €1.25 billion aggregate principal amount (the "Offering") of the following euro-denominated notes:

  • €500,000,000 aggregate principal amount of its 3.200% senior notes due 2026 (the "2026 notes"), at the issue price of 99.965% of their principal amount, and
  • €750,000,000 aggregate principal amount of its 3.650% senior notes due 2034 (the "2034 notes" and together with the 2026 notes, the "notes"), at the issue price of 99.637% of their principal amount.

The Offering is expected to close on or about November 21, 2022, subject to customary closing conditions. The notes will pay interest on an annual basis.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×